MSH|^~\&|LAB|SMH|||201912101639||ORU^R01|4126704|D|2.3|||AL|NE
PID|1||SM00044280|SM44111|LABTEST^AIR^PRESTO||19870323|M||||||||||SM005225/18|9875450974
OBR|1|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.0890^HEPBSAG^Hep B Surface Antigen -Active^^^XBC411-0||201912040857|201912040857|||||||201912040857||||||||||LAB|F||||
OBX|1|ST|523.0815^HEPBSAB BMARKER^Hepatitis B Markers^HBSAG^5193-8^5193-8|1|31.1^^N|mIU/mL||N||A^S|F|||201912101639
OBX|2|ST|523.0907^HEPBSAG R^Hepatitis B Surface Antigen^XXX^5196-1^5196-1|1|Nonreactive.^^N|||N||A^S|F|||201912101639
OBX|3|ST|523.1120^HEPBCORTOT NP^Hepatitis B Core Total Ab^XXX^51914-0^51914-0|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||Hepatitis B Interpretation:
NTE|2||No evidence of HBV infection, patient is immune to HBV likely from vaccination.
OBR|2|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.1390^HEPC^Hep C Antibody^^^13955-0||201912040857|201912040857|||||||201912040857||||||||||LAB|F||||
OBX|1|ST|523.1410^HEPC R^Hepatitis C Antibody^HEPCB^13955-0^13955-0|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||No evidence of HCV infection.
OBR|3|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.1895^HIV^HIV -Nominal Reporting^^^75666-8||201912040857|201912040857|||||||201912040857||||||||||LAB|F||||
OBX|1|ST|523.19061^HIV EIA4G^HIV 1 and 2 Ab/Ag EIA Screen^HIVCC^XXX-2887^XXX-2887|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||No evidence of HIV infection.
OBR|4|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.1975^HIVRAP^Rapid HIV^^^7918-6||201912040857|201912040857|||||||201912040857||||||||||LAB|I||||

MSH|^~\&|LAB|SMH|||201912101639||ORU^R01|4126705|D|2.3|||AL|NE
PID|1||SM00044280|SM44111|LABTEST^AIR^PRESTO||19870323|M||||||||||SM005225/18|9875450974
OBR|1|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.0890^HEPBSAG^Hep B Surface Antigen -Active^^^XBC411-0||201912040857|201912040857|||||||201912040857||||||||||LAB|F||||
OBX|1|ST|523.0815^HEPBSAB BMARKER^Hepatitis B Markers^HBSAG^5193-8^5193-8|1|31.1^^N|mIU/mL||N||A^S|F|||201912101639
OBX|2|ST|523.0907^HEPBSAG R^Hepatitis B Surface Antigen^XXX^5196-1^5196-1|1|Nonreactive.^^N|||N||A^S|F|||201912101639
OBX|3|ST|523.1120^HEPBCORTOT NP^Hepatitis B Core Total Ab^XXX^51914-0^51914-0|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||Hepatitis B Interpretation:
NTE|2||No evidence of HBV infection, patient is immune to HBV likely from vaccination.
OBR|2|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.1390^HEPC^Hep C Antibody^^^13955-0||201912040857|201912040857|||||||201912040857||||||||||LAB|F||||
OBX|1|ST|523.1410^HEPC R^Hepatitis C Antibody^HEPCB^13955-0^13955-0|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||No evidence of HCV infection.
OBR|3|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.1895^HIV^HIV -Nominal Reporting^^^75666-8||201912040857|201912040857|||||||201912040857||||||||||LAB|F||||
OBX|1|ST|523.19061^HIV EIA4G^HIV 1 and 2 Ab/Ag EIA Screen^HIVCC^XXX-2887^XXX-2887|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||No evidence of HIV infection.
OBR|4|36438^LAB|00027632^0412:CS00001R^LAB^041219:CS1^36438|523.1975^HIVRAP^Rapid HIV^^^7918-6||201912040857|201912040857|||||||201912040857||||||||||LAB|I||||

MSH|^~\&|LAB|SMH|||201912101639||ORU^R01|4126706|D|2.3|||AL|NE
PID|1||SM00044881|SM44687|LABTEST^FOXGLOVE^||20181205|M||||||||||SM000864/19|9875310262
OBR|1|36446^LAB|00027639^0412:CS00005R^LAB^041219:CS5^36446|523.1895^HIV^HIV -Nominal Reporting^^^75666-8||201912041001|201912041001|||||||201912041001||||||||||LAB|F||||
OBX|1|ST|523.19061^HIV EIA4G^HIV 1 and 2 Ab/Ag EIA Screen^HIVCC^XXX-2887^XXX-2887|1|Equivocal.^^N|||H||A^S|F|||201912101639

MSH|^~\&|LAB|CGH|||201912101639||ORU^R01|4126707|D|2.3|||AL|NE
PID|1||CG00002237|CG2208|LABTEST^CGHDXHUPGRADEMALEJRSR^||19850307|M||||||||||CG000037/19|9875060325
OBR|1|36443^LAB|00027636^0412:CS00002R^LAB^041219:CS2^36443|523.2395^SYPHSE^Syphilis Serology Screen (RPR)^^^22464-2||201912040939|201912040938|||||||201912040938||||||||||LAB|F||||
OBX|1|ST|523.2415^SYPHEIA^Syphillis T.pallidum EIA^TPE^24110-9^24110-9|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||If primary syphilis is suspected, send a repeat test in 2 weeks.
NTE|2||HIV testing is recommended for all persons tested for sexually transmitted
NTE|3||infections.

MSH|^~\&|LAB|CGH|||201912101639||ORU^R01|4126708|D|2.3|||AL|NE
PID|1||CG00002006|CG2006|LABTEST^TENNIS^||19781010|F||||||||||CG000006/17|
OBR|1|36447^LAB|00027640^0412:CS00006R^LAB^041219:CS6^36447|523.4280^MEASLIGG^Measles IgG -Immunity^^^35275-7||201912041004|201912041004|||||||201912041004||||||||||LAB|F||||
OBX|1|ST|523.4290^MEASLIGG R^Measles IgG (Immunity)^MIGB^35275-7^35275-7|1|Reactive.^^N|||N||A^S|F|||201912101639
NTE|1||Immune to Measles from vaccination or past infection.
NTE|2||Patient previously tested reactive on specimen collected 25 December 2008.
NTE|3||There has been no change in the serological pattern compared to the previous
NTE|4||specimen collected on 25 December 2008. Please
NTE|5||submit a follow up specimen if clinically indicated.
NTE|6||Dr. Doyle discussed with Dr.
NTE|7||Smith on 09 December 2019. Test performed at the BCCDC Public Health
NTE|8||Laboratory. For test performance characteristics or for consultation, please
NTE|9||see http://www.elabhandbook.info.

MSH|^~\&|LAB|CGH|||201912101639||ORU^R01|4126709|D|2.3|||AL|NE
PID|1||CG00002218|BH4309|LABTEST^OLIVE^OIL||19690215|F||||||||||CG000006/19|9875848962
OBR|1|36445^LAB|00027638^0412:CS00004R^LAB^041219:CS4^36445|523.1895^HIV^HIV -Nominal Reporting^^^75666-8||201912040959|201912040959|||||||201912040959||||||||||LAB|F||||
OBX|1|ST|523.19061^HIV EIA4G^HIV 1 and 2 Ab/Ag EIA Screen^HIVCC^XXX-2887^XXX-2887|1|Nonreactive.^^N|||N||A^S|F|||201912101639
NTE|1||No evidence of HIV infection.